INOVIO Pharmaceuticals
NEWS ALERT

Clinical and Immunological Results from Phase 1/2 Study of INO-3107 as a treatment for Recurrent Respiratory Papillomatosis Published in Nature Communications

Press Releases

Data from Phase 1b trial with INO-4201 as an Ebola Booster for rVSV-ZEBOV (Ervebo®) presented at ECCMID 2023

Posted on April 17, 2023

INOVIO Announces Acceptance of Abstract for Oral Presentation on INO-4201 as an Ebola Booster for rVSV-ZEBOV (Ervebo®) at ECCMID 2023

Posted on April 12, 2023

INOVIO Reports Inducement Grant Under Inducement Plan

Posted on April 3, 2023

INOVIO to Present at the Oppenheimer 33rd Annual Healthcare Conference

Posted on March 3, 2023

INOVIO Reports Fourth Quarter and Full Year 2022 Financial Results and Clinical Highlights

Posted on March 1, 2023

INOVIO Announces Positive Preliminary Results from Second Cohort of Phase 1/2 Trial with INO-3107 for the Treatment of Recurrent Respiratory Papillomatosis

Posted on February 16, 2023

INOVIO to Report Fourth Quarter and Year-End 2022 Financial Results on March 1, 2023

Posted on February 15, 2023

INOVIO Reports Positive Phase 1b Results for INO-4201 as an Ebola Booster for rVSV-ZEBOV (Ervebo®)

Posted on February 2, 2023

INOVIO Announces Strategic Reorganization, Continues Efforts to Focus on Promising DNA Medicine Candidates

Posted on January 31, 2023

INOVIO Provides an Update on Lassa Fever and MERS Programs

Posted on November 17, 2022

SUBSCRIBE FOR UPDATES FROM INOVIO
Register to receive email alerts for INOVIO press releases

© Copyright 2025 INOVIO Pharmaceuticals. All rights reserved.